Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2020

View Archived Issues

Positive interim phase III data released for lenzilumab in hospitalized patients with COVID-19

FDA approves Brilinta to reduce the risk of stroke in acute ischemic stroke or high-risk TIA

Phase II study of ABTL-0812 in pancreatic cancer approved in the U.S. and Spain

Spanish researchers patent new HDAC6 inhibitors

Rottapharm Biotech divulges protein kinase inhibitors

Janssen Biotech presents DHODH inhibitors

Seres Therapeutics initiates phase Ib study of SER-301 in ulcerative colitis

Azeria Therapeutics synthesizes new SGK inhibitors

Synerkine Pharma discloses new IL-13-comprising fusion proteins

PARP inhibition can help out tumor cells

SASH3 mutations associated with a new X-linked combined immunodeficiency

Revving up cisplatin by targeting Rev7

HIP1R variants linked to a recessive, progressive, neurologic disorder

USP48 gene tied to nonsyndromic hereditary hearing loss

Organoids enable tumor genotype-phenotype mapping

CaMK4 as potential target to slow cyst growth in PKD

SARS-CoV-2 spike proteins directly activate the APC, which can be blocked by factor D inhibition

New markers identified for kidney disease and its prognosis

FDA approves Sesquient to treat status epilepticus in adult and pediatric patients

Phase III trial of Nefecon in primary IgAN meets key endpoints

7 Hills Pharma begins first-in-human study of integrin activator 7HP-349

Phase III interim analysis shows COVID-19 vaccine efficacy rate above 90% with BNT-162b2

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...